BeiGene Ltd (NASDAQ: ONC) stock soared 5.79% in pre-market trading on Thursday, February 27, 2025, following the company's strong financial results for the fourth quarter and full year 2024, coupled with an upbeat revenue guidance for 2025.
The global oncology company reported better-than-expected revenue for Q4 2024, driven by robust sales growth of its flagship product BRUKINSA. Total revenue for the quarter stood at $1.13 billion, a 78% increase from the year-ago period, surpassing analyst estimates of $1.04 billion.
For the full year 2024, BeiGene's total revenue reached $3.81 billion, up 55% year-over-year, fueled by the strong performance of BRUKINSA in the U.S. and Europe. The company achieved positive non-GAAP operating income for the full year, despite reporting a GAAP operating loss.
Looking ahead, BeiGene provided an optimistic outlook for 2025, projecting total revenue between $4.9 billion and $5.3 billion, exceeding analysts' expectations of $4.73 billion. The company expects to achieve positive GAAP operating income and generate positive cash flow from operations in 2025, driven by BRUKINSA's continued leadership position in the U.S. and global expansion.
BeiGene's management highlighted the company's progress in advancing its solid tumor pipeline, with multiple data readouts anticipated in the first half of 2025. The company also emphasized its commitment to developing innovative and accessible cancer treatments worldwide.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。